Shares of Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE – Get Free Report) have been assigned an average rating of “Moderate Buy” from the seven brokerages that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have given a buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $10.00.
Several research analysts have recently weighed in on the stock. Craig Hallum set a $2.00 target price on shares of Alterity Therapeutics in a research report on Tuesday, August 11th. Weiss Ratings downgraded shares of Alterity Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, November 4th. UBS Group set a $12.00 price target on shares of Alterity Therapeutics in a research report on Tuesday, August 11th. Finally, Lake Street Capital assumed coverage on shares of Alterity Therapeutics in a research note on Tuesday, September 15th. They issued a “buy” rating and a $10.00 price objective for the company.
Check Out Our Latest Report on Alterity Therapeutics
Alterity Therapeutics Price Performance
Shares of ATHE opened at $1.70 on Thursday. The business’s 50-day moving average price is $2.88 and its 200 day moving average price is $3.89. Alterity Therapeutics has a 1-year low of $1.70 and a 1-year high of $5.89.
Alterity Therapeutics (NASDAQ:ATHE – Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($0.28) EPS for the quarter. The business had revenue of $0.31 million for the quarter. On average, equities research analysts anticipate that Alterity Therapeutics will post -0.12 earnings per share for the current year.
Institutional Trading of Alterity Therapeutics
An institutional investor recently raised its stake in Alterity Therapeutics stock. Greenleaf Trust grew its holdings in Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE – Free Report) by 93.8% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 62,000 shares of the company’s stock after purchasing an additional 30,000 shares during the period. Greenleaf Trust owned approximately 0.70% of Alterity Therapeutics worth $333,000 as of its most recent SEC filing. 2.14% of the stock is currently owned by institutional investors and hedge funds.
Alterity Therapeutics Company Profile
Alterity Therapeutics is an Australian clinical-stage biotechnology company developing treatments for neurodegenerative diseases. Its research focuses on conditions associated with abnormal protein accumulation and disrupted iron balance in the brain, including multiple system atrophy (MSA) and Parkinson’s disease. The company’s lead candidate, ATH434, is an investigational small-molecule therapy being studied for MSA. Alterity is evaluating the treatment in clinical trials; it is not an approved medicine.
See Also
- Five stocks we like better than Alterity Therapeutics
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Alterity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alterity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
